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Abstract 
 BACKGROUND: Progressive stroke (PS) and Crescendo Transient Ischemic Attacks (CTIA) is a 
generally accepted although unproven, indication for urgent intravenous anticoagulation therapy. 
 METHODS: Consecutive patients with PS and CTIA admitted in Ghaem hospital, Mashhad dur-
ing 2007 - 2008 enrolled in a prospective clinical study. PS and CTIA patients underwent intra-
venous heparin therapy with 1000 units per hour without a bolus dose at least for 3 days. PS and 
CTIA patients who had a contraindication for intravenous heparin therapy, received 80 mg As-
pirin per day. Early clinical course including improvement, stabilization, deterioration and de-
velopment of residual stroke was evaluated in two therapeutic groups of PS and CTIA patients. 
 RESULTS: 170 PS patients (103 males, 67 females) with mean age of 60.4 ± 12.3 years and 88 
CTIA patients (50 males, 38 females) with mean age of 60.1 ± 6.8 years were assessed. 141 PS 
and 64 CTIA patients received short period intravenous heparinization. Distribution of subtypes 
of early clinical course between two therapeutic groups of PS and CTIA patients, was significant-
ly different; X2 = 10.487, df = 2, P = 0.005 and X2 = 6.72, df = 2, P = 0.035 respectively. Distri-
bution of residual stroke in two therapeutic groups of PS and CTIA patients, was not significant-
ly different; X2 = 1.443, df = 1, P = 0.23, OR = 0.557 (0.212-1.462) and X2 = 1.01, df = 1,  
P = 0.315, OR = 0.617 (0.24-1.587) respectively. 
 CONCLUSION: PS and CTIA patients who underwent short period intravenous heparin ther-
apy have significantly more probability of improvement and less probability of deterioration in 
their early clinical course than PS and CTIA patients who received Aspirin therapy. 
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Neurological deficits of ischemic stroke, are frequently 
unstable during early phase of stroke. Patients my show 
progressive deterioration with stepwise or nonstepwise 
fashions or fluctuations with periods of improvement1. 
Stroke in evolution is a non-specific term and is not 
synonymous with thrombosis in evolution.1 Almost 
30% of stroke patients worsen after entery to the hos-
pital.1 Common practice considers that heparin fol-
lowed by warfarin is indicated if observation provides 
clear evidence of recognizable worsening of an ischem-
ic neurological disability.2 This practice has been based 
on incomplete and largely anecdotal data.2 In progres-
sive stroke (PS), the focal ischemia worsens over sever-
al hours, or a day or two.1,2 Progression of stroke in a 
stepwise fashion is easier to regard as stroke due to 
repeated episodes of thromboembolism than indolent-
ly PS.3,4 Patients exhibiting stepwise progression ,may 
theoretically be considered as likely to benefit from 
anticoagulation.3,4 Conversely, patients who develop 
neurologic deficit in a nonstepwise progressing fashion, 
probably are not exhibiting progressive thrombus for-
mation and will not be expected to respond to anticoa-
gulation.3,4 Brain edema accounts for most of the pro-
gression in the later situation.2 Multiple or Crescendo 
Transient Ischemic Attacks (CTIA) are frequent in 
clinical practice. The term CTIA defined as occurance 
of multiple episodes over a few hours or days, often 
with increasing duration or severity.5 Some studies sug-
gest that CTIA may represent a condition of impend-
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ing brain infarction.6 Common medical practice re-
commends short term anticoagulation in patients with 
CTIA without proven efficacy.5 CTIA and major TIA 
require urgent evaluation and admission of the patient 
.4 This observational study compared the clinical course 
of PS and CTIA patients who received short term 
intravenous heparin therapy with similar patients who 
took ultra low dose of Aspirin.  
Materials and Methods 
Consecutive patients with PS and CTIAs who were 
admitted in Ghaem hospital, Mashhad during 2007- 
2008, enrolled in a prospective observational study. 
The research was approved by ethics committee of 
Ghaem hospital. A signed informed consent was tak-
en from the patients or their first degree relatives. 
 PS was defined as stepwise or fluctuated worsen-
ing of focal neurological deficits over several hours, 
or a day or two.1,2,7 These deficits could increase in 
severity, extent or number.1,2,7  
 CTIA was defined as two transient ischemic at-
tacks(TIAs) within 24 hours, three TIAs within 3 days or 
4 TIAs within 2 weeks.1,7 These crescendo attacks are 
often increasing in duration and in severity of deficit.1,5, 
 Patients with CTIA were evaluated for presence of 
motor, sensory, aphasic and amarotic disturbances. 
Consecutive patients with PS and CTIA underwent 
intravenous heparin therapy with 1000 units per hour 
without an initial bolus dose at least for 3 days. PS 
patients with coma, dense hemiplegia  or extensive 
signs of ischemia in the initial CT (more than one-
third of a hemisphere) and PS and CTIA patients with 
a contraindication for anticoagulation therapy were 
excluded.8 Antiplatelet drugs and warfarin were not 
administered during intravenous heparinization in this 
3 days.8 A brain CT was done for exclusion of intra-
cranial hemorrhage before initiation of heparin thera-
py in all of these patients.8,9 Prothromin Time, Partial 
Thromboplastin Time and International Normalized 
Ratio were evaluated before anticoagulation therapy 
and thereafter ,once a day during heparin therapy.9 PS 
and CTIA patients who had an initially abnormal coa-
gulation tests were excluded.9 Short term intravenous 
heparin therapy in these patients is a routine thera-
peutic strategy in our instituation.2,5 PS and CTIA 
patients with a contraindication of intravenous hepa-
rin therapy ,received Aspirin 80 mg per day during 
hospitalization period.2,5 The National Institute of 
Health Stroke Scale (NIHSS) was detected in all of 
patients with PS and CTIA before heparinization and 
3 days later.10 The clinical course of these patients was 
categorized as improvement, stabilization and deteri-
oration.11 Improvement was defined as ≥3 points de-
crease and deterioration as ≥ 3 points increase in the 
second NIHSS.10,11 Other patients were assumed as 
stabilization group.10,11 The same NIHSS assessment 
was perform in PS and CTIA patients who received 
Aspirin therapy.10,11 Presence of stroke at 3 days after 
anticoagulation therapy was evaluated in all of our 
patients with PS and CTIA. All of these patients had a 
repeated CT after anticoagulation therapy for investi-
gation of a visible infarct. A residual stroke was de-
fined as the presence of ischemic focal neurological 
deficit lasting more than 24 hours or observation of a 
hypodense lesion in the CT corresponding to the ma-
nifestations.11 Demographic and clinical data of the 
patients recorded in a SPSS11.5 software. Pearson Chi-
Square and Fisher tests served for statistical anaslysis. 
Results 
170 patients (103 males, 67 females) with mean age of 
60.4 ± 12.3 years developed PS. 141 PS patients (84 
males, 57 female) underwent short term intravenous 
heparin therapy and 29 PS patients (19 males, 10 fe-
males) received Aspirin 80 mg per day. Assessment of 
early stroke course in two therapeutic groups of PS 
patients is presented in Figure 1. Frequency rate of 
subtypes of early stroke course was significantly dif-
ferent in our two therapeutic groups of PS patients; 
X2 = 10.487, df = 2, P = 0.005. The influence of gend-
er on early course of PS was not significant in the he-
parin and aspirin therapy groups; (X2 = 0.063, df = 2,  
P = 0.969) and (X2 = 0.021, df = 2, P = 0.990) respec-
tively. 119 PS patients including 68.1% of heparin and 
79.3% of Aspirin groups, developed a residual stroke. 
Distribution of residual stroke was not significantly 
different in our two groups of PS patients; X2 = 1.443, 
df = 1, P = 0.23, OR = 0.557 (0.212-1.462). Distribu-
tion of residual stroke based on the gender was not 
significantly different in PS patients who received short 
term intravenous heparinization; X2 = 0.089, df = 1,  
P = 0.766, OR = 1.11 (0.543-2.29). Difference in fre-
quency of residual stroke according to the gender, was 
not significant in PS patients who had on Aspirin;  
X2 = df = 1, P = 0.947, OR=0.938 (0.140-6.28). A re-
sidual stroke developed in 30% of improvement, 100% 
of stabilization and 100% of deterioration courses 
among 170 PS patients. 88 patients (50 males, 38 fe-
males) with mean age of 60.1 ± 6.8 years had CTIA. 64 
patients (36 males, 28 females) with CTIA, underwent 
short term intravenous heparinization and 24 CTIA 
patients (14 males, 10 females) received Aspirin, 80 mg 
per day. Difference in distribution of residual stroke in 
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two groups of CTIA patients was not significant;  
X2 = 1.01, df = 1, P = 0.315, OR = 0.612 (0.24-1.587). 
The effect of gender on frequency of residual stroke in 
CTIA patients who received short term intravenous 
heparinization was not significant; X2 = 0.367, df = 1, 
P = 0.545, OR, 0.734 (0.27-1.997). Distribution of re-
sidual stroke was not significantly different according 
to the gender in CTIA patients who received aspirin 
therapy; X2=0.12, df = 1, P = 0.729, OR = 1.33 (0.261-
6.801). Frequency of early clinical course in two thera-
peutic groups of CTIA patients, was significantly dif-
ferent; X2 = 6.72, df = 2, P = 0.035. Distribution of 
early clinical course was not significantly different 
based on the gender in CTIA patients who received 
short period intravenous heparinization and aspirin 
therapy (X2 = 0.12, df = 2, P = 0.941 and X2 = 0.171, 
df = 2, P = 0.918) respectively. Figure 2 illustrates 
early clinical course of 88 CTIA patients in our two 
therapeutic groups. Motor, sensory, aphasic and ama-
rotic manifestations were found in 48%, 19%, 15% 
and 2% of our CTIA cases respectively. Two PS and 
one CTIA cases had minor hemorrhagic complica-
tions of intravenous anticoagulation including echy-
mosis and hematuria  
 
Fig 1. Frequency rate of stroke course in two therapeutic 
groups of PS patients. 















Fig 2. Frequency rate of early clinical course in two thera-
peutic groups of CTIA patients  
Data are presented in percentage in each group separately. 
Discussion  
Clinical trials suggested a beneficial effect of anticoagu-
lation therapy in PS patients. 3,4Based on the results of 
these trials, the indication for heparin therapy in this 
condition, became widely accepted.2,5 Other studies 
have not been conclusive in indication of anticoagula-
tion therapy for PS patients, however overview of 
whole related studies suggested that, heparin therapy 
reduces the risk of PS.1,2,12 Meanwhile, lack of precise 
criteria for entry and outcome, non-blinded observa-
tion and small number of patients ,makes these studies 
inadequate by current methodological standards.2,5,13 
The main reason that 72 hours was selected as cut off  
point in assessment of our patients, is that progression 
period is usually completed in 72 hours.1 At the other 
side some of these patients are practically discharged in 
3-4 days after anticoagulation therapy and extention of 
hospitalization time only for research is not possible 
ethically. Use of intravenous heparin therapy in PS pa-
tients, is still a matter of controversity in recent years.14 
Although short term intravenous heparinization, dem-
onstrated no significant influence on development of 
residual stroke in our PS patients, however it has con-
firmed a significant influence on early stroke course in 
PS patients. PS patients on short period intravenous 
heparinization, had significantly more probability for 
improvement and less probability for deterioration. 
Heparin therapy is widely used for clustering or CTIA.2 
This therapeutic strategy for TIA derived by extrapo-
lating results of intravenous anticoagulation therapy for 
PS.2,5 Although intravenous heparin therapy is recom-
mended for CTIA, the data supporting its efficacy, 
derived from old and limited studies.15 However, intra-
venous heparinization has been shown to be a safe 
therapeutic method in these cases.15 Despite reports of 
safety in administration of bolus of intravenous heparin 
administration, bolus dose of heparin was not admins-
tered in our PS and CTIA patients and none of them 
developed major hemorrhagic complications.16 There 
remains relatively evidence-free practice of using hepa-
rin in patients with CTIAs.14 Although short period 
intravenous heparin therapy was associated with a non 
significant decrease on frequency of residual stroke in 
our CTIA patients, however patients who underwent 
this therapy had better clinical course.  Common prac-
tice of neurologists, about using intravenous heparin 
therapy in patients with PS and CTIA is different. Neu-
rologists of United States more frequently use intraven-
ous heparin therapy in PS and CTIA patients than Ca-
nadian neurologists (51% versus 33%) and (47% versus 
9%) respectively.17 The main reason of this difference 
is the effect of medicolegal factors on the neurolo-
gists.17 Up to date therapeutic guidelines of American 
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and Europian stroke associations, do not recommend 
short term intravenous anticoagulation in PS and CTIA 
patients.18,19 This management is recommended in 
textbooks of cerebrovascular disease and is the routine 
therapeutic strategy in our department.2,5,8 Since low 
dose Aspirin therapy is recommended as a standard 
management for PS and CTIA patients, it is not ethi-
cally possible to compare intravenous heparin therapy 
with placebo in these patients.  Thus we compared 
intravenous heparin therapy with ultra low dose of As-
pirin. Although our clinical study suggests intravenous 
heparinization in PS and CTIA patients, however ran-
domized and double blind clinical trials is recommend-
ed in this concept. 
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